Mycophenolate mofetil monotherapy in liver transplantation.
Chronic renal failure is a major cause of morbidity and mortality after orthotopic liver transplantation. We did a randomised controlled trial of mycophenolate mofetil monotherapy in liver transplant patients who developed renal failure associated with calcineurin-inhibitor (ciclosporin or tacrolimus) immunosuppressive therapy. Although renal failure improved when the calcineurin-inhibitor dose was reduced and ultimately stopped, the trial was stopped when three of five patients on monotherapy developed organ rejection requiring a second transplantation.
Stewart
S F
SF
Hudson
M
M
Talbot
D
D
Manas
D
D
Day
C P
CP
D065095:Calcineurin Inhibitors; D002908:Chronic Disease; D016572:Cyclosporine / Q000009:adverse effects*; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016031:Liver Transplantation; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000139:chemically induced*; D016559:Tacrolimus / Q000009:adverse effects*
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D007168:IMP Dehydrogenase; D009173:Mycophenolic Acid; D016559:Tacrolimus